TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.26 per share a year ago.